Results 21 to 30 of about 693,798 (288)

Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) : a systematic structured review of the literature [PDF]

, 2007
Adverse events triggered by non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common drug-related intolerance reactions in medicine; they are possibly related to inhibition of cyclooxygenase-1.
Weberschock, Tobias Bernd Bernd, Boehncke, Wolf-Henning, Tobias Bernd Weberschock, Sylke-Monina Müller, Sandra Boehncke, Müller, Sylke-Monina, Wolf-Henning Boehncke, Weberschock, Tobias Bernd, Boehncke, Sandra   +8 more
core   +1 more source

Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants [PDF]

Korean Journal of Pediatrics, 2017
PurposePlasma level of B-type natriuretic peptide (BNP), an emerging, sensitive, and specific biomarker of hemodynamically significant patent ductus arteriosus (PDA), rapidly decreases in infants receiving cyclooxygenase inhibitors for ductal closure. We
Jeonghee Shin, Eun Hee Lee, Jee Hyun Lee, Byung Min Choi, Young Sook Hong   +4 more
doaj   +1 more source

Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats.

PLoS ONE, 2019
Nonsteroidal anti-inflammatory drugs and acetaminophen are cyclooxygenase inhibitors commonly used as symptomatic medicines for myofascial pain syndrome.
Tetsuhiro Shimodaira, Shigeo Mikoshiba, Toru Taguchi   +2 more
doaj   +1 more source

Novel biphasic role of lipoxinA4 on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts [PDF]

, 2011
Fibroblasts are important to host defence and immunity, can also as initiators of inflammation as well. As the endogenous "braking signal", Lipoxins can regulate anti-inflammation and the resolution of inflammation.
Gao, F., Song, X. R., QingQuan Lian, Jin, Shengwei, Shengxing Zheng, Duyun Ye, He, Q., Fang Gao, Jin, S. W., Gao, Fang; id_orcid, Xiaorong Song, He, Qian, Qian Wang, Ye, Duyun, Wang, Q., Zheng, Shengxing, Ye, D. Y., Lian, Q. Q., Lian, QingQuan, Shengwei Jin, Song, Xiaorong, Qian He, Wang, Qian, Smith, F. Gao (Fang Gao), Zheng, S. X.   +24 more
core   +1 more source

Cyclooxygenase 2 (COX-2) inhibitors

, 2022
Ciklooksigenaza-2 (engl. Cyclooxygenase-2, COX-2) je enzim koji se pojavljuje u bolnim i upaljenim tkivima, dok je u zdravim tkivima uglavnom neaktivan.
Magić, Dina
core   +2 more sources

Update on Cyclooxygenase-2 Inhibitors [PDF]

Clinical Journal of the American Society of Nephrology, 2006
Nonsteroidal anti-inflammatory drugs represent the most commonly used medications for the treatment of pain and inflammation, but numerous well-described side effects can limit their use. Cyclooxygenase-2 (COX-2) inhibitors were initially touted as a therapeutic strategy to avoid not only the gastrointestinal but also the renal and cardiovascular side ...
Raymond C, Harris, Matthew D, Breyer
openaire   +2 more sources

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer [PDF]

, 2007
Background Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal ...
Christopher C. McConkey, Justine L. Smith, McConkey, Christopher C., Midgley, RS, Kerr, DJ, Janet A. Dunn, Stokes, JC, Midgley, Rachel, Claire Iveson, McConkey, CC, HASH(0x55a67f94f158), Midgley, Rachel S. J., HASH(0x55a67f45c688), Iveson, Claire, David J. Kerr, Ravi Duvvuri, Iveson, C, Patrick Julier, Julier, P, Smith, JL, Joanne C. Stokes, Langman, Michael J., Julier, Patrick, Duvvuri, Ravi, Rachel S.J. Midgley, Smith, Justine L., Michael J. Langman, Dunn, Janet A., Duvvuri, R, Kerr, David J., Kerr, David, Langman, MJ, Stokes, Joanne C., Andrew Stanley, Stanley, A, Dunn, JA, Stanley, Andrew   +36 more
core   +1 more source

Cyclooxygenase-2 inhibitors: promise or peril?

Mediators of Inflammation, 2002
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized ...
Laurel J. Mengle-Gaw, Benjamin D. Schwartz   +1 more
doaj   +1 more source

Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis [PDF]

, 2010
Background: Squamous cell carcinoma of the head and neck (SCCHN) are highly invasive tumours with frequent local and distant recurrence. Metastasis formation requires degradation of the extracellular matrix, which is fulfilled by membrane-associated ...
Olivier Gires, Muehlenweg Bernd, Pamela Zengel, Muehlenweg, Bernd, Gires, Olivier, Ramp, D., Gires, O., Alexander Berghaus, Gires Olivier, Mack, Brigitte, Zengel, Pamela, Zahler, Stefan, Muehlenweg, B., Diana Ramp, Stefan Zahler, Mack, B., Bernd Muehlenweg, Zahler, S., Berghaus Alexander, Mack Brigitte, Zengel, P., Suna Schmitz, Berghaus, Alexander, Schmitz, Suna, Schmitz, S., Ramp, Diana, Schmitz Suna, Zahler Stefan, Zengel Pamela, Brigitte Mack, Ramp Diana, Berghaus, A.   +31 more
core   +2 more sources

The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation

Mediators of Inflammation, 1998
Lipopolysaccharide is an inflammatory agent and interleukin-1 is a cytokine. Their pro-inflammatory effects may be mediated by prostanoids produced by inducible cyclooxygenase-2.
W. E. Longo, L. J. Damore, J. E. Mazuski, G. S. Smith, N. Panesar, D. L. Kaminski   +5 more
doaj   +1 more source